{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:24:46Z","timestamp":1750832686295},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.061","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T20:35:22Z","timestamp":1712262922000},"page":"2945-2950","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Holly E.","family":"Baum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Thirard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Baos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosie A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Culliford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hitchings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Goenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeka","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.061_b0005","unstructured":"PHE England. COVID-19 vaccine surveillance report (Week 5) 2 February 2023. https:\/\/assets.publishing.service.gov.uk\/media\/63dcd993e90e075d9ff98165\/vaccine-surveillance-report-week-5-2023.pdf."},{"key":"10.1016\/j.vaccine.2024.03.061_b0010","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.03.061_b0015","doi-asserted-by":"crossref","unstructured":"Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Cla\u00ebr L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Science Translational Medicine vol. 13. 2021. doi: 10.1126\/scitranslmed.abd2223.","DOI":"10.1126\/scitranslmed.abd2223"},{"issue":"172","key":"10.1016\/j.vaccine.2024.03.061_b0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bdj.4807861","article-title":"Saliva: its secretion, composition and functions","volume":"1992","author":"Edgar","year":"1992","journal-title":"Br Dent J"},{"key":"10.1016\/j.vaccine.2024.03.061_b0025","doi-asserted-by":"crossref","first-page":"20401","DOI":"10.3402\/jom.v5i0.20401","article-title":"Secretory immunity with special reference to the oral cavity","volume":"5","author":"Brandtzaeg","year":"2013","journal-title":"J Oral Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.061_b0030","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2024.03.061_b0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2024.03.061_b0040","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/vaccines11040744","article-title":"Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens","volume":"11","author":"Alkharaan","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.03.061_b0045","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.2147\/IDR.S369769","article-title":"Durability of SARS-CoV-2 specific IgG antibody responses following two doses of match and mixed COVID-19 vaccines regimens in saudi population","volume":"15","author":"Mubarak","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.vaccine.2024.03.061_b0050","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","article-title":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial","volume":"398","author":"Lazarus","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2024.03.061_b0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s43856-023-00264-2","article-title":"Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults","volume":"3","author":"Thomas","year":"2023","journal-title":"Commun Med"},{"key":"10.1016\/j.vaccine.2024.03.061_b0060","doi-asserted-by":"crossref","unstructured":"Halliday A, Long AE, Baum HE, Thomas AC, Shelley KL, Oliver E, et al. Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2. Front Immunol 2022;13. doi: 10.3389\/fimmu.2022.968317.","DOI":"10.3389\/fimmu.2022.968317"},{"key":"10.1016\/j.vaccine.2024.03.061_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101323","article-title":"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial","volume":"45","author":"Pitisuttithum","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.03.061_b0070","doi-asserted-by":"crossref","unstructured":"Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, et al. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? EMBO Mol Med 2022;14. doi: 10.15252\/emmm.202115326.","DOI":"10.15252\/emmm.202115326"},{"key":"10.1016\/j.vaccine.2024.03.061_b0075","doi-asserted-by":"crossref","unstructured":"Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine 2023;87. doi: 10.1016\/j.ebiom.2022.104402.","DOI":"10.1101\/2022.09.09.22279759"},{"key":"10.1016\/j.vaccine.2024.03.061_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953949","article-title":"mRNA vaccination drives differential mucosal neutralizing antibody profiles in na\u00efve and SARS-CoV-2 previously-infected individuals","volume":"13","author":"Longet","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.061_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33550-z","article-title":"Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study","volume":"13","author":"Shrotri","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.03.061_b0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.vaccine.2019.11.067","article-title":"The use and abuse of a 4-fold increase in antibody response to assess immunogenicity in early stage vaccine clinical trials","volume":"38","author":"Saul","year":"2020","journal-title":"Vaccine"},{"issue":"183\u201395","key":"10.1016\/j.vaccine.2024.03.061_b0095","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"103841","key":"10.1016\/j.vaccine.2024.03.061_b0100","article-title":"Intranasal COVID-19 vaccines: From bench to bed-NC-ND license (http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/)","volume":"76","author":"Alu","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2024.03.061_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32389-8","article-title":"SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:54:35Z","timestamp":1725688475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003670"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}